TrialNerd_Beth said:anders_CPH said: ...cardiovascular risk is just another fad...
Same experience, arrived at from the opposite direction.
TrialNerd_Beth said:anders_CPH said: ...cardiovascular risk is just another fad...
I want to bring up the cardiovascular angle on cardiovascular risk.
The SELECT trial demonstrated a 20% reduction in MACE with semaglutide 2.4mg[1]. This is practice-changing because the CV benefit appears to be independent of the degree of weight loss — suggesting direct vascular and anti-inflammatory mechanisms.
For cardiovascular risk, this means we need to think beyond the primary outcome and consider the cardiovascular implications. The all-cause mortality reduction (HR 0.81) is the most clinically meaningful signal.
TrialNerd_Beth said:anders_CPH said: ...cardiovascular risk is just another fad...
Senior perspective on cardiovascular risk: I'm 69 years old and started this journey skeptically. My geriatrician recommended it after years of failed interventions.
9 months later: down 47 lbs, more mobile, pain reduced, medications simplified. My quality of life has improved dramatically. I wish this existed 20 years ago.
To other older adults hesitating: the SELECT trial proved benefit in our age group. You deserve to feel good in your body regardless of age.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemFollowing on from TrialNerd_Beth — and this may be the naive question:
Was that from a primary source or from a summary of one?
PeptideSynthNJ said:Senior perspective on cardiovascular risk: I'm 69 years old and started this journey skeptically.
6 month update on cardiovascular risk: down 48 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.